Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 8 |
| List of Tables | 9 | 2 |
| List of Figures | 11 | 2 |
| Introduction | 13 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Market Overview | 14 | 3 |
| Market Characterization and Forecasts | 14 | 1 |
| Revenue by Geographical Segmentation | 15 | 2 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Australia | 17 | 10 |
| Registration Process and Regulations | 17 | 3 |
| Market Characterization and Forecasts | 20 | 1 |
| Cost of Vaccination | 21 | 1 |
| Vaccination Pattern | 22 | 1 |
| Population | 22 | 1 |
| Vaccinated Population Contribution | 23 | 1 |
| Vaccination Coverage | 24 | 1 |
| Number of Doses per Person | 24 | 1 |
| Total Number of Doses | 25 | 1 |
| Dose Contribution | 25 | 1 |
| Drivers and Barriers | 26 | 1 |
| Drivers | 26 | 1 |
| Government Support for Immunization against Seasonal Influenza | 26 | 1 |
| Restraints | 26 | 1 |
| Seasonal Influenza Vaccines Kept Out of Pharmaceutical Benefits Scheme | 26 | 1 |
| Incidences of Adverse Reactions after Vaccination | 26 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific China | 27 | 9 |
| Registration Process and Regulations | 27 | 2 |
| Market Characterization and Forecasts | 29 | 1 |
| Cost of Vaccination | 30 | 1 |
| Vaccination Pattern | 31 | 1 |
| Population | 31 | 1 |
| Vaccinated Population Contribution | 32 | 1 |
| Vaccination Coverage | 33 | 1 |
| Number of Doses per Person | 33 | 1 |
| Total Number of Doses | 34 | 1 |
| Dose Contribution | 34 | 1 |
| Competitive Landscape | 35 | 1 |
| Drivers and Barriers | 35 | 1 |
| Drivers | 35 | 1 |
| High Awareness due to Pandemic Influenza | 35 | 1 |
| Availability of Low-cost Flu Vaccines | 35 | 1 |
| Barriers | 35 | 1 |
| Absence of a National Influenza Vaccination Program | 35 | 1 |
| Lack of Manufacturing Capacity | 35 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Hong Kong | 36 | 10 |
| Registration Process and Regulations | 36 | 2 |
| Market Characterization and Forecasts | 38 | 1 |
| Cost of Vaccination | 39 | 1 |
| Vaccination Pattern | 40 | 1 |
| Population | 40 | 1 |
| Vaccinated Population Contribution | 41 | 1 |
| Vaccination Coverage | 42 | 1 |
| Number of Doses per Person | 42 | 1 |
| Total Number of Doses | 43 | 1 |
| Dose Contribution | 43 | 1 |
| Competitive Landscape | 44 | 1 |
| Drivers and Barriers | 45 | 1 |
| Drivers | 45 | 1 |
| Low Price of Seasonal Influenza Vaccine | 45 | 1 |
| Government Programs for Seasonal Influenza Vaccination | 45 | 1 |
| Restraints | 45 | 1 |
| Low Government Contribution | 45 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific India | 46 | 6 |
| Registration Process and Regulations | 46 | 3 |
| Market Characterization and Forecasts | 49 | 1 |
| Cost of Vaccination | 50 | 1 |
| Drivers and Barriers | 51 | 1 |
| Drivers | 51 | 1 |
| Increasing Awareness of Seasonal Influenza | 51 | 1 |
| Low-cost Vaccine Expected to be Available in the Future | 51 | 1 |
| Barriers | 51 | 1 |
| Low Vaccination Coverage for Seasonal Influenza | 51 | 1 |
| Absence of a National Influenza Vaccination Program | 51 | 1 |
| Absence of Low-cost Domestic Manufacturers of Seasonal Influenza Vaccines in India | 51 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Japan | 52 | 10 |
| Registration Process and Regulations | 52 | 2 |
| Market Characterization and Forecasts | 54 | 1 |
| Cost of Vaccination | 55 | 1 |
| Vaccinated Population | 56 | 1 |
| Population | 56 | 1 |
| Vaccinated Population Contribution | 57 | 1 |
| Vaccination Coverage | 58 | 1 |
| Number of Doses per Person | 58 | 1 |
| Total Number of Doses | 58 | 2 |
| Drivers and Restraints | 60 | 1 |
| Drivers | 60 | 1 |
| Influenza Immunization Program | 60 | 1 |
| Incidences of Pandemic Influenza | 60 | 1 |
| Rapidly Growing Elderly Population | 60 | 1 |
| Subsidized Immunization for the Elderly | 60 | 1 |
| Barriers | 61 | 1 |
| Non-reimbursement of Influenza Vaccination Costs | 61 | 1 |
| Limited Availability Period for Subsidized Vaccines | 61 | 1 |
| Lack of Scientific Studies Establishing Safety and Efficacy of Flu Vaccines in Japan | 61 | 1 |
| High Vaccine Cost | 61 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Malaysia | 62 | 10 |
| Registration Process and Regulations | 62 | 2 |
| Market Characterization and Forecasts | 64 | 1 |
| Cost of Vaccination | 65 | 1 |
| Vaccination Pattern | 66 | 1 |
| Population | 66 | 1 |
| Vaccinated Population Contribution | 67 | 1 |
| Vaccination Coverage | 68 | 1 |
| Number of Doses per Person | 68 | 1 |
| Total Number of Doses | 69 | 1 |
| Dose Contribution | 69 | 1 |
| Competitive Landscape | 70 | 1 |
| Drivers and Barriers | 71 | 1 |
| Drivers | 71 | 1 |
| Rapidly Increasing Vaccination Coverage | 71 | 1 |
| Barriers | 71 | 1 |
| Low Government Contribution | 71 | 1 |
| Low Overall Coverage | 71 | 1 |
| High Price of Vaccine | 71 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific New Zealand | 72 | 10 |
| Registration Process and Regulations | 72 | 2 |
| Market Characterization and Forecasts | 74 | 1 |
| Cost of Vaccination | 75 | 1 |
| Vaccination Pattern | 76 | 1 |
| Population | 76 | 1 |
| Vaccinated Population Contribution | 77 | 1 |
| Vaccination Coverage | 78 | 1 |
| Number of Doses per Person | 78 | 1 |
| Total Number of Doses | 79 | 1 |
| Dose Contribution | 79 | 1 |
| Competitive Landscape | 80 | 1 |
| Drivers and Barriers | 81 | 1 |
| Drivers | 81 | 1 |
| Increasing Vaccination Coverage | 81 | 1 |
| Government Support for Immunization | 81 | 1 |
| Low Vaccine Price | 81 | 1 |
| Barriers | 81 | 1 |
| Low Vaccination Coverage for Influenza in Children | 81 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Philippines | 82 | 10 |
| Registration Process and Regulations | 82 | 2 |
| Market Characterization and Forecasts | 84 | 1 |
| Cost of Vaccination | 85 | 1 |
| Vaccination Pattern | 86 | 1 |
| Population | 86 | 1 |
| Vaccinated Population Contribution | 87 | 1 |
| Vaccination Coverage | 88 | 1 |
| Number of Doses per Person | 88 | 1 |
| Total Number of Doses | 89 | 1 |
| Dose Contribution | 89 | 1 |
| Competitive Landscape | 90 | 1 |
| Drivers and Barriers | 91 | 1 |
| Drivers | 91 | 1 |
| Population Growth | 91 | 1 |
| Rapid Increase in Vaccination Coverage | 91 | 1 |
| Restraints | 91 | 1 |
| Low Government Contribution | 91 | 1 |
| High Price of Vaccine | 91 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Singapore | 92 | 9 |
| Registration Process and Regulations | 92 | 1 |
| Market Characterization and Forecasts | 93 | 1 |
| Cost of Vaccination | 94 | 1 |
| Vaccination Pattern | 95 | 1 |
| Population | 95 | 1 |
| Vaccinated Population Contribution | 96 | 1 |
| Vaccination Coverage | 97 | 1 |
| Number of Doses per Person | 97 | 1 |
| Total Number of Doses | 98 | 1 |
| Dose Contribution | 98 | 1 |
| Competitive Landscape | 99 | 1 |
| Drivers and Barriers | 100 | 1 |
| Drivers | 100 | 1 |
| Rapidly Increasing Vaccination Coverage | 100 | 1 |
| Increase in Elderly Population | 100 | 1 |
| Barriers | 100 | 1 |
| Low Government Contribution | 100 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Taiwan | 101 | 10 |
| Registration Process and Regulations | 101 | 2 |
| Market Characterization and Forecasts | 103 | 1 |
| Cost of Vaccination | 104 | 1 |
| Vaccination Pattern | 105 | 1 |
| Population | 105 | 1 |
| Vaccinated Population Contribution | 106 | 1 |
| Vaccination Coverage | 107 | 1 |
| Number of Doses per Person | 107 | 1 |
| Total Number of Doses | 108 | 1 |
| Dose Contribution | 108 | 1 |
| Competitive Landscape | 109 | 1 |
| Drivers and Barriers | 110 | 1 |
| Drivers | 110 | 1 |
| Growth in Elderly Population | 110 | 1 |
| Government Support for Immunization | 110 | 1 |
| Low Price of Vaccine | 110 | 1 |
| Restraints | 110 | 1 |
| Stagnating Vaccination Coverage | 110 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific - Pipeline Analysis | 111 | 10 |
| Pipeline Analysis by Phase | 111 | 5 |
| Product Profiles of Promising Molecules | 116 | 1 |
| Optaflu | 117 | 1 |
| Overview | 117 | 1 |
| Efficacy | 117 | 1 |
| Safety | 117 | 1 |
| Clinical Study Details | 117 | 1 |
| GSK2186877A | 117 | 1 |
| Overview | 117 | 1 |
| Efficacy | 117 | 1 |
| Safety | 117 | 1 |
| Clinical Study Details | 118 | 1 |
| Intanza/Flu-ID | 118 | 1 |
| Overview | 118 | 1 |
| Efficacy | 118 | 1 |
| Safety | 118 | 1 |
| Clinical Study Details | 118 | 1 |
| Fluad Pediatric | 119 | 1 |
| Overview | 119 | 1 |
| Efficacy | 119 | 1 |
| Safety | 119 | 1 |
| Clinical Study Details | 119 | 1 |
| FluBlok | 119 | 1 |
| Overview | 119 | 1 |
| Product Profiles of Marketed Products | 120 | 1 |
| Fluarix | 120 | 1 |
| Vaxigrip | 120 | 1 |
| Influvac | 120 | 1 |
| Fluvax | 120 | 1 |
| Agrippal | 120 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Competitive Landscape | 121 | 2 |
| Sanofi Pasteur | 121 | 1 |
| GlaxoSmithKline Biologicals | 121 | 1 |
| Abbott Laboratories (Solvay Pharmaceuticals) | 121 | 1 |
| CSL Biotherapies | 121 | 1 |
| Novartis Vaccines | 122 | 1 |
| Crucell N.V. (Berna Biotech) | 122 | 1 |
| Seasonal Influenza Vaccine Market in Asia-Pacific Strategic Consolidations | 123 | 8 |
| Overview | 123 | 1 |
| Major Merger and Acquisition Deals, 2007 2012 | 123 | 1 |
| AstraZeneca Acquires Medimmune | 124 | 1 |
| Sanofi-Aventis (now Sanofi) Acquires Acambis | 124 | 1 |
| Mymetics Acquires Virosome Biologicals | 124 | 1 |
| Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock | 124 | 1 |
| Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan | 125 | 1 |
| Abbott Laboratories Acquires Solvay Pharmaceuticals | 125 | 1 |
| Nutri Pharma Acquires a Majority Stake in Bionor Immuno | 125 | 1 |
| Johnson &Johnson Acquires Crucell | 125 | 1 |
| GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals | 125 | 1 |
| M&A Deals by Geography | 126 | 1 |
| Major Licensing Agreements, 2007 2012 | 127 | 1 |
| Crucell Enters into License Agreement with Adimmune Corporation | 127 | 1 |
| MedImmune Enters into Licensing Agreement with Sanofi Pasteur | 127 | 1 |
| Vivalis Enters into Licensing Agreement with GlaxoSmithKline | 127 | 1 |
| Vivalis Enters into Licensing Agreement with Nobilon International | 127 | 1 |
| MedImmune Enters into Licensing Agreement with GlaxoSmithKline | 127 | 1 |
| Hemispherx Biopharma Enters into Licensing Agreement with Biken | 128 | 1 |
| MedImmune Enters into Licensing Agreement with Biken | 128 | 1 |
| MedImmune Enters into Licensing Agreement with Omninvest | 128 | 1 |
| OPKO Health Enters into Licensing Agreement with Academia Sinica | 128 | 1 |
| Altravax Enters into Licensing Agreement with Maxygen | 128 | 1 |